Sign in

    Gursimran Kaur • Wells Fargo & Company

    Gursimran Kaur's questions to STAAR Surgical Co (STAA) leadership

    Gursimran Kaur's questions to STAAR Surgical Co (STAA) leadership • Q1 2025

    Question

    Gursimran Kaur from Wells Fargo & Company inquired about how new leadership is shaping China strategy and the expected pace of recovery there. She also asked for specifics on the U.S. business inefficiencies that prompted recent cost-cutting measures.

    Answer

    President and COO Warren Foust explained that the new APAC leadership, including interim Chief Wei Zhang, provides high-level, co-located strategic oversight to capitalize on opportunities in the region. CEO Steve Farrell expressed confidence in a strong second half in China, citing rising procedure volumes and normalized inventory levels. Regarding U.S. cost cuts, Foust noted the need to right-size investments relative to the market's revenue contribution, while Farrell added that the cuts primarily address underutilized facilities and bring SG&A back to a successful 2023 run-rate level.

    Ask Fintool Equity Research AI

    Gursimran Kaur's questions to Merit Medical Systems Inc (MMSI) leadership

    Gursimran Kaur's questions to Merit Medical Systems Inc (MMSI) leadership • Q1 2025

    Question

    Gursimran Kaur, on for Larry Biegelsen, inquired about the specific drivers of softer demand in China and asked for more detail on the tariff impact, including the percentage of China sales manufactured in the U.S.

    Answer

    EVP and CFO Raul Parra attributed the softness to variability in the OEM business but noted the overall demand fundamentals were in line and the full-year China guidance is unchanged. He declined to provide specific manufacturing breakdowns but reiterated that 94% of the $26.3 million tariff impact is related to China, primarily from goods imported into the country.

    Ask Fintool Equity Research AI

    Gursimran Kaur's questions to Merit Medical Systems Inc (MMSI) leadership • Q3 2024

    Question

    Gursimran Kaur of Wells Fargo, on for Larry Biegelsen, asked for confirmation that WRAPSODY would be priced at a significant premium to meet the cost criteria for add-on payments. She also requested more detail on the commercial strategy, including sales force positioning and launch readiness post-FDA approval.

    Answer

    Executive Joseph Wright confirmed that pricing WRAPSODY at a premium is a 'fair assumption' to meet the NTAP criteria, with more details to be shared post-approval. Executive Fred Lampropoulos added that the company is actively preparing on all fronts—clinical, regulatory, reimbursement, and commercial—and will provide a comprehensive update in a virtual meeting after securing FDA approval.

    Ask Fintool Equity Research AI